Yahoo Web Search

  1. Ads
  1. After the Federal Trade Commission (FTC) demanded Bristol-Myers Squibb (NYSE: BMY) sell its blockbuster Otezla to secure approval for its $74 billion acquisition of Celgene ...

  2. Near an All-Time Low, Is Clovis Oncology a Buy?

    Motley Fool via Yahoo FinanceSep 04 10:00 AM

    Clovis Oncology has been in a fierce competition to expand the use of Rubraca, the company's poly ADP ribose polymerase (PARP) inhibitor, before other drugs in its class can carve out ...

  3. Could the Trade War be Bullish for Stocks?

    Zacks via Yahoo FinanceSep 11 16:05 PM

    Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. This week ...

  4. AVEO Surges on Favorable Updated OS Results on RCC Drug

    Zacks via Yahoo FinanceSep 11 15:40 PM

    Notably, Aug 15, 2019 was the data cut-off date for the second prespecified OS analysis, almost a 10-month gap from the data cut-off date for the first prespecified analysis. additional OS events ...

  5. Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug

    Zacks via Yahoo FinanceSep 12 13:09 PM

    Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.

  6. 7 Cheap Stocks to Buy in a Pricey Market

    Kiplinger via Yahoo FinanceSep 10 17:38 PM

    Here are seven of their favorite cheap stocks to buy. Financial adviser Scott Pederson, of Harmony Wealth Management LLC in Crown Point, Indiana, says energy is cheap, and that within the sector ...

  7. 25 Dividend Stocks That Analysts Love the Most

    Kiplinger via Yahoo FinanceSep 11 19:54 PM

    Analysts forecast the bank to generate average annual earnings growth of 7.8% over the next three to five years, according to data from S&P Global Market Intelligence. Add in a yield of more ...

  8. Novartis Announces New Data on Spondylitis Drug Cosentyx

    Zacks via Yahoo FinanceSep 17 15:05 PM

    Swiss pharma giant Novartis AG NVS announced positive new data from the ongoing PREVENT study on spondylitis drug, Cosentyx (secukinumab). PREVENT is an ongoing two-year randomized, double-blind ...

  9. Seth Klarman's Favorite Health Care Stocks via Yahoo FinanceSep 12 23:25 PM

    In the first half of this year, Klarman has placed almost a quarter of his portfolio into the lagging health care sector, among the highest levels of the past decade. Klarman's hedge fund, the ...

  10. The news comes a week after Bristol-Myers Squibb Co said its blockbuster cancer immunotherapy, Opdivo, failed a late-stage trial testing it in patients with glioblastoma ...

  1. Ads